Annovis Bio, Inc.

ANVS Healthcare Biotechnology

In the quarter to June 2026, EPS fell 25.0% and free cash flow fell 329.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.99 0.06 −5.71%
Market cap
$44.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(703.68%) (301.13%) (220.61%) (246.14%)

+8 more TTM periods

ROA
(227.74%) (190.43%) (164.85%) (157.74%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(315.88%) (1,185.13%) (165.39%) (184.94%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(1.16) (0.95) (1.25) (1.27)
Free Cash Flow
(43.34) (26.53) (25.62) (24.98)
Other line items

Show all line items

Columns are period end dates